Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

BACKGROUND: The phase 3 VIALE-A trial (NCT02993523) reported that venetoclax-azacitidine significantly prolonged overall survival compared with placebo-azacitidine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy. Herein, efficacy and safety of venetoclax...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Kazuhito, Shinagawa, Atsushi, DiNardo, Courtney D, Pratz, Keith W, Ishizawa, Kenichi, Miyamoto, Toshihiro, Komatsu, Norio, Nakashima, Yasuhiro, Yoshida, Chikashi, Fukuhara, Noriko, Usuki, Kensuke, Yamauchi, Takahiro, Asada, Noboru, Asou, Norio, Choi, Ilseung, Miyazaki, Yasushi, Honda, Hideyuki, Okubo, Sumiko, Kurokawa, Misaki, Zhou, Ying, Zha, Jiuhong, Potluri, Jalaja, Matsumura, Itaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242001/
https://www.ncbi.nlm.nih.gov/pubmed/34739075
http://dx.doi.org/10.1093/jjco/hyab170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242001/
https://www.ncbi.nlm.nih.gov/pubmed/34739075
http://dx.doi.org/10.1093/jjco/hyab170

Ejemplares similares